Felodipine is a new dihydropyridine calcium channel blocker which is effective in reducing blood pressure by decreasing peripheral resistance due to its selectivity of the smooth muscle in the resistance arteriolar vessels. This was done to assess antihypertensive activity and tolerability of an extended-release (ER) formulation of felodipine 10 mg WHO stages I and II single dose with placebo in mildly hypertensive patients. It involved a total of 50 patients who were randomly selected into either felodipine or placebo in a 4-week cross-over study shedding light to the last 4 weeks of single-blinded placebo treatment. The measurement of the blood pressure and heart rate was conducted after dosing 22-24 hours. The findings demonstrated that felodipine lowered systolic and diastolic blood pressure (9 and 8 mmHg, respectively) substantially as opposed to placebo without having an impact on the heart rate. There were minimal side effects when using the 10 mg dose of felodipine and these effects were comparable to the ones that conventional formulations have. The experiment proves that the delayed release Intervention in felodipine can effectively achieve 24 hours flux control in blood pressure and implies that its effect was not dissimilar to regular patients adherence and that it has added great value to the antihypertensive treatment

Medicated chewing gums have become an alternative oral drug delivery system in response to their promise of ease of use, increased patient compliance, and improved bioavailability. The purpose of this study was to develop and test medicated chewing gums with Hydroxyzine hydrochloride, an antihistamine that is used to treat anxiety, nausea, and motion sickness. Pharmagum M was used as the gum base, and hydroxyzine was loaded into the matrix base of the gum, with different excipients to enhance the release of the drug. The formulations were evaluated on organoleptic properties, pre-compression, and post-compression properties such as drug content, hardness, friability and in vitro drug release. The findings showed that the formulations were able to give a controlled and sustained release of Hydroxyzine with formulation MCG4 having the best release of the drug (95.88%) in 30 minutes. The paper also noted the effect of gum base and magnesium stearate on drug launch rate. The stability analyses indicated that MCG4 had preserved its physical and chemical stability during accelerated storage environments. The results indicate that medicated chewing gums serve as a viable and patient-friendly alternative to traditional forms of oral medication, and improved therapeutic benefits could be realized by the use of medicated chewing gums in the management of acute disorders such as anxiety and nausea